Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …
[HTML][HTML] Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity
CBN Lauson, S Tiberti, PA Corsetto, F Conte, P Tyagi… - Cell Metabolism, 2023 - cell.com
The metabolic state represents a major hurdle for an effective adoptive T cell therapy (ACT).
Indeed, specific lipids can harm CD8+ T cell (CTL) mitochondrial integrity, leading to …
Indeed, specific lipids can harm CD8+ T cell (CTL) mitochondrial integrity, leading to …
Management of hepatocellular carcinoma: a review
Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
Immunotherapies for hepatocellular carcinoma
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
Immune cell-mediated features of non-alcoholic steatohepatitis
T Huby, EL Gautier - Nature reviews immunology, 2022 - nature.com
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …
The immunological and metabolic landscape in primary and metastatic liver cancer
X Li, P Ramadori, D Pfister, M Seehawer… - Nature Reviews …, 2021 - nature.com
The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …
A researcher's guide to preclinical mouse NASH models
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …
[HTML][HTML] NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …